Structured, confidential coordination for international families seeking access to Switzerland's leading fertility institutions — IVF, genetic testing, fertility preservation, and comprehensive reproductive care
If you are navigating fertility decisions right now, you are likely balancing hope, exhaustion, and the pressure of time all at once. You may have already completed tests or previous cycles, yet still feel uncertain about where to continue and how to coordinate each step without losing privacy or momentum. In this phase, families often need more than information: they need a calm, structured pathway with clear sequencing, controlled communication, and reliable institutional coordination.
For strategic context, review the executive medical access framework in Switzerland to understand governance, confidentiality standards, and non-clinical coordination boundaries across specialties.
SwissAtlas is not a medical institution. We do not provide medical advice, diagnosis, or treatment recommendations. Our role is to facilitate structured, confidential coordination between international families and trusted Swiss fertility institutions. The sensitive and personal nature of fertility treatment requires particular care in handling all communications and logistics.
Switzerland's fertility institutions combine rigorous regulatory oversight, advanced laboratory technology, comprehensive genetic testing capabilities, and a strong emphasis on patient privacy — creating an environment of trust and clinical excellence for one of medicine's most intimate journeys.
SwissAtlas operates as a structured institutional coordination platform, not a medical directory or information service. Our role is to facilitate confidential, curated introductions between international families and trusted Swiss medical institutions that have demonstrated institutional excellence, regulatory compliance, and a commitment to the highest standards of patient care.
SwissAtlas does not provide medical advice, diagnostic assessments, or treatment recommendations. We do not evaluate, rank, or endorse specific medical institutions, physicians, or clinical programmes. Our coordination function is strictly non-clinical and administrative, encompassing the structuring and secure transmission of medical documentation, the identification of relevant institutional options based on the family's stated requirements, and the management of logistical and administrative dimensions of the patient journey.
The relationship between the patient and the treating medical institution remains direct and independent. SwissAtlas serves as an intermediary layer that handles administrative coordination, documentation management, appointment scheduling, accommodation planning, transport logistics, and communication facilitation — all while maintaining the highest standards of discretion and confidentiality consistent with Swiss data protection legislation.
Swiss institutions operate under rigorous regulatory oversight at both federal and cantonal levels, ensuring institutional quality, clinical governance, and patient safety. The Swiss Federal Act on Data Protection provides among the strongest privacy protection frameworks globally, creating an environment where sensitive medical information is handled with the utmost care and legal protection.
For international families considering ivf / fertility coordination in Switzerland, SwissAtlas provides a structured pathway that reduces administrative complexity, ensures proper documentation handling, and facilitates efficient engagement with appropriate institutional partners. This coordination model is designed for families who value discretion, structured processes, and institutional-level service delivery.
SwissAtlas's ivf / fertility coordination services are designed for international families and individuals who require structured, confidential access to Swiss medical institutions. The following profiles typically engage with our coordination platform:
This coordination service is not designed for routine medical consultations or standard healthcare needs that can be addressed through conventional channels. SwissAtlas focuses on cases that require structured institutional coordination, administrative precision, and the level of discretion and service delivery that characterises Switzerland's private healthcare coordination model.
Infertility is a prevalent condition affecting an estimated one in six couples of reproductive age worldwide, according to the WHO (2023 report). The WHO recognises infertility as a disease of the reproductive system and acknowledges its significant psychological, emotional, and social impact. Globally, over 186 million people live with infertility.
The causes of infertility are approximately equally distributed between female factors (ovulatory disorders, tubal damage, endometriosis, uterine abnormalities), male factors (sperm quality and quantity abnormalities, obstructive and non-obstructive azoospermia), combined factors, and unexplained infertility. Age is the single most significant factor affecting female fertility, with a progressive decline in both egg quantity and quality from the mid-30s, accelerating after 37.
The European Society of Human Reproduction and Embryology (ESHRE) reports that over 1 million IVF cycles are performed annually in Europe alone, resulting in over 200,000 births per year. Since the birth of the first IVF baby in 1978, an estimated 12 million children have been born through assisted reproductive technologies worldwide. The OECD notes significant variation in access to and regulation of fertility treatment across countries, which contributes to international patient movement for reproductive care.
Comprehensive fertility evaluation forms the foundation of any treatment plan. Female assessment typically includes hormonal profiling (FSH, LH, oestradiol, AMH — anti-Müllerian hormone as a marker of ovarian reserve, thyroid function, prolactin), pelvic ultrasound with antral follicle count (AFC), hysterosalpingography (HSG) or hysterosalpingo-contrast sonography (HyCoSy) to assess tubal patency, hysteroscopy to evaluate the uterine cavity, and potentially genetic screening (karyotype, fragile X, thrombophilia panel).
Male assessment includes semen analysis (concentration, motility, morphology), hormonal evaluation (FSH, LH, testosterone), and where indicated, genetic testing (karyotype, Y-chromosome microdeletion analysis, CFTR mutations), sperm DNA fragmentation assessment, and urological evaluation. For couples with recurrent pregnancy loss, additional investigations including immunological screening, antiphospholipid antibody testing, and uterine assessment are typically performed.
In vitro fertilisation involves several carefully orchestrated stages. Ovarian stimulation — using injectable gonadotropins (FSH, LH) — promotes the development of multiple follicles. Stimulation protocols (long agonist, short antagonist, mild stimulation) are tailored to the patient's ovarian reserve, age, and previous response. Regular transvaginal ultrasound and blood hormone monitoring guide dosage adjustments. Trigger injection (hCG or GnRH agonist) induces final oocyte maturation approximately 36 hours before retrieval.
Oocyte retrieval is performed transvaginally under ultrasound guidance with sedation, typically taking fifteen to thirty minutes. Fertilisation occurs in the laboratory using conventional IVF (placing sperm around the oocyte) or intracytoplasmic sperm injection (ICSI — injecting a single sperm directly into the oocyte). ICSI is the standard approach for male factor infertility, low oocyte numbers, or previous fertilisation failure.
Embryo culture in controlled laboratory conditions for five to six days to the blastocyst stage enables better embryo selection based on morphological and kinetic criteria. Time-lapse imaging systems — standard at leading Swiss centres — allow continuous monitoring of embryo development without removing embryos from the incubator, providing additional selection information. Embryo transfer involves placing the selected embryo(s) into the uterus through a fine catheter — a brief, painless procedure typically performed without anaesthesia.
ICSI is an advanced fertilisation technique in which a single sperm cell is selected and injected directly into the cytoplasm of a mature oocyte using a micropipette. This technique is indicated for severe male factor infertility, surgically retrieved sperm (TESA, MESA, micro-TESE), previous IVF fertilisation failure, and cycles using frozen oocytes or requiring preimplantation genetic testing. ICSI fertilisation rates typically range from 70–80% of mature oocytes.
Since the 2017 legislative revision, Switzerland permits preimplantation genetic testing (PGT). PGT-A (aneuploidy screening) evaluates the chromosomal complement of embryos, identifying those with normal chromosome numbers (euploid) for preferential transfer. This is particularly relevant for women over 37 and patients with recurrent implantation failure or pregnancy loss. PGT-M (monogenic disease testing) screens embryos for specific inherited genetic conditions when one or both parents are carriers — such as cystic fibrosis, sickle cell disease, thalassaemia, Huntington's disease, and many others.
Testing involves trophectoderm biopsy (removing a few cells from the outer cell layer of the blastocyst), followed by genetic analysis using next-generation sequencing (NGS). Embryos are vitrified during analysis, with transfer of selected embryos in a subsequent frozen embryo transfer cycle. This approach has significantly improved per-transfer pregnancy rates and reduced miscarriage rates, particularly in older patients.
Vitrification (ultra-rapid freezing) has revolutionised embryo cryopreservation, with post-thaw survival rates exceeding 95% at experienced centres. Frozen embryo transfer (FET) cycles are increasingly common as the evidence base supporting elective freeze-all strategies grows. FET allows endometrial preparation optimised for embryo implantation, separate from the hormonal effects of ovarian stimulation. Natural cycle FET, modified natural cycle FET, and hormone-replacement cycle FET are all available approaches, selected based on the patient's menstrual regularity and clinical factors.
Fertility preservation has become an increasingly important aspect of reproductive medicine. Oocyte vitrification for social or age-related fertility preservation allows women to store eggs at their current biological age for future use. Swiss centres report oocyte survival rates exceeding 90% after vitrification. For cancer patients facing gonadotoxic treatment, emergency fertility preservation can typically be arranged within one to two weeks, coordinated with the oncology team. Ovarian tissue cryopreservation offers an option for prepubertal patients or those unable to undergo stimulation. Sperm cryopreservation is widely available and is recommended before any treatment that may impair fertility.
For men with obstructive or non-obstructive azoospermia (absence of sperm in the ejaculate), surgical sperm retrieval techniques enable biological fatherhood through ICSI. TESA (testicular sperm aspiration), MESA (microsurgical epididymal sperm aspiration), and micro-TESE (microsurgical testicular sperm extraction) are performed by urologists specialising in male reproductive medicine. Micro-TESE — using an operating microscope to identify areas of active spermatogenesis — offers the highest retrieval rates for non-obstructive azoospermia.
Swiss fertility treatment is governed by the Federal Act on Medically Assisted Reproduction (FMedG), revised in 2017. This legislation provides a clear, ethical framework that balances patient access with protective safeguards. Key provisions include: treatment available to married and unmarried heterosexual couples; development of up to twelve embryos per cycle; PGT-A and PGT-M permitted; embryo cryopreservation for up to ten years; single embryo transfer recommended; egg donation and gestational surrogacy prohibited; sperm donation permitted with identity disclosure at age 18; sex selection for non-medical reasons prohibited. Swiss fertility centres are licensed, regularly inspected, and required to report outcomes to national registries. This regulatory environment provides international patients with assurance that treatment is conducted within a well-defined ethical and legal framework.
Rigorous regulatory oversight. Strong privacy protections. PGT-A and PGT-M available since 2017. Personalised care with lower patient volumes. Transparent cost structure. No egg donation. Costs between Spanish and US levels. Advanced laboratory technology including time-lapse imaging.
Most liberal regulatory framework globally. Egg donation, surrogacy, and comprehensive genetic testing widely available. Highest treatment costs internationally. Broadest clinical trial access. Variable regulatory oversight by state. Strong success rates at leading centres.
Leading European destination for IVF with egg donation. Anonymous egg donation legally permitted. Competitive costs, generally below Swiss levels. High volumes and established programmes. Shorter waiting times for egg donation cycles. Good success rates.
Significantly lower costs. Modern facilities at selected centres. Regulatory framework permits IVF for married couples. PGT available. Egg donation and surrogacy not permitted. Important to verify centre-specific success rates and laboratory quality.
IVF treatment costs vary by protocol complexity, medication requirements, laboratory procedures (ICSI, PGT, vitrification), and number of cycles needed. Swiss centres provide transparent, itemised estimates. Costs are generally competitive with Northern European centres and substantially below US equivalents. Medication costs, which represent a significant proportion of total IVF expenses, are generally lower in Switzerland than in the US. SwissAtlas provides general guidance; specific estimates come from the treating centre.
International healthcare mobility represents a significant and growing dimension of the global health landscape. The OECD has documented increasing cross-border patient movement driven by factors including access to specialised expertise, waiting time differentials, regulatory framework considerations, and the pursuit of clinical environments aligned with individual patient expectations regarding quality, privacy, and care coordination. The World Health Organization recognises that patient mobility raises important considerations related to continuity of care, quality assurance, data protection, and ethical standards — all of which must be addressed within structured institutional frameworks.
Switzerland occupies a distinctive position within this landscape. The Swiss healthcare system consistently ranks among the highest-performing globally according to multiple indices, characterised by universal access, high per-capita healthcare expenditure, strong regulatory oversight, and a decentralised institutional model that fosters both competition and quality. For international patients seeking fertility care, Switzerland's institutional positioning reflects several structural advantages: regulatory predictability under federal and cantonal legislation, strong institutional governance frameworks, comprehensive data protection under the Federal Act on Data Protection (FADP), and a long-established tradition of receiving international patients within a culture of discretion and institutional integrity.
The coordination of international patient pathways within this institutional context requires structured administrative facilitation that bridges the gap between the patient's home healthcare environment and the Swiss institutional framework. This coordination function — distinct from any clinical or advisory role — ensures that administrative, logistical, and communicative dimensions of the patient journey are managed with the same level of professionalism and precision that characterises Swiss institutional healthcare delivery. [Internal link: Why Switzerland Private Healthcare]
The international patient coordination pathway for fertility care in Switzerland follows a structured sequence designed to ensure administrative clarity, institutional alignment, and logistical precision at every stage. This pathway operates independently of all clinical decision-making, which remains exclusively within the domain of the patient and their treating medical professionals.
The coordination process begins with a confidential enquiry, during which the patient or their representative provides a general description of the medical situation and coordination requirements. All communications are handled under strict confidentiality protocols consistent with Swiss data protection legislation. No medical assessment or clinical opinion is provided at this stage or at any subsequent stage of the coordination process.
Existing medical documentation — including diagnostic imaging, laboratory results, pathology reports, operative notes, and clinical correspondence — is organised into a structured format suitable for institutional review. This administrative function ensures that the relevant Swiss institution receives a complete, organised, and properly formatted file, facilitating efficient preliminary assessment by the institution's clinical team.
Based on the general nature of the clinical situation and the patient's expressed requirements — including language preferences, privacy considerations, geographical preferences within Switzerland, and logistical factors — appropriate Swiss institutions with relevant reproductive medicine capabilities are identified. This process is informational and facilitative only; no clinical recommendation or institutional ranking is provided. The patient retains complete autonomy in institutional selection. [Internal link: Private Coordination Services]
Once the patient has selected an institution and the clinical team has confirmed the proposed evaluation or treatment pathway, comprehensive pre-arrival logistics are coordinated. This includes appointment scheduling, accommodation arrangements near the treating institution, transport logistics, visa documentation support where required, interpreter arrangements, and cultural accommodation planning — including dietary requirements and any specific needs.
During the active treatment phase, coordination services ensure that administrative and logistical dimensions continue to function seamlessly. This includes communication facilitation between the patient's family and institutional administrative contacts, schedule coordination for multiple appointments or procedures, accommodation management, and practical support for accompanying family members. All clinical matters remain under the exclusive direction of the treating medical team.
For cases requiring post-treatment rehabilitation — which is particularly relevant in fertility care — coordination services extend to the identification and arrangement of appropriate rehabilitation facilities, transfer logistics, communication continuity between the treating institution and the rehabilitation team, and ongoing family support. Switzerland's extensive rehabilitation infrastructure provides a range of options suited to different clinical requirements and personal preferences.
The final phase of coordination addresses the patient's transition back to their home healthcare environment. This includes facilitation of comprehensive medical summary transmission to the patient's home-country physicians, coordination of follow-up schedules, arrangement of any required medical equipment or medication for the return journey, and establishment of communication channels for ongoing institutional follow-up as directed by the treating medical team. [Internal link: International Patient Process]
The handling of medical data in the context of international patient coordination requires the highest standards of security, confidentiality, and regulatory compliance. Switzerland's legal framework for data protection — governed by the Federal Act on Data Protection (FADP, revised 2023) and supplemented by cantonal health legislation — provides one of the most comprehensive privacy protection regimes globally. The FADP imposes strict requirements on the processing, storage, transmission, and retention of personal data, including heightened protections for health-related information classified as sensitive personal data.
Within this legal framework, all medical documentation transmitted as part of the coordination process is handled using secure, encrypted communication channels. Access to patient files is restricted to authorised personnel on a strict need-to-know basis. No medical data is retained beyond the period required for the specific coordination mandate, and data deletion protocols are applied in accordance with the patient's instructions and applicable legal requirements.
Swiss medical professional secrecy — a legal obligation enforceable under the Swiss Criminal Code (Article 321) — provides an additional layer of protection that applies to all healthcare professionals involved in the patient's care. Breach of medical professional secrecy is a criminal offence in Switzerland, providing a level of legal deterrence that reinforces institutional confidentiality commitments.
For international patients from jurisdictions with differing data protection standards, Switzerland's independent data protection framework — recognised by the European Commission as providing an adequate level of protection — offers significant assurance regarding the handling of sensitive medical information. The coordination process is designed to maintain compliance with both Swiss data protection requirements and, where applicable, the data protection obligations of the patient's home jurisdiction.
The international second opinion represents an established component of evidence-based medical practice, particularly relevant for complex fertility situations requiring advanced reproductive technologies and genetic evaluation. The value of independent expert review is well-documented in medical literature, with studies demonstrating that second opinions result in meaningful changes to diagnosis or treatment recommendations in a significant proportion of cases. For international patients, accessing a second opinion within a different institutional and healthcare system provides an additional dimension of independence and objectivity.
Fertility second opinions are sought when previous IVF cycles have been unsuccessful, when the diagnosis is uncertain, when the proposed treatment escalation raises questions, or when patients wish to explore alternative protocols before proceeding. Independent expert review typically involves reassessment of ovarian reserve markers, re-evaluation of previous cycle parameters (stimulation response, oocyte yield, fertilisation rates, embryo quality), review of uterine factors, and comprehensive male factor analysis. For patients with recurrent implantation failure or recurrent pregnancy loss, a systematic independent evaluation can identify previously unrecognised factors and suggest modified approaches that may improve outcomes.
The coordination of an international second opinion follows a structured pathway: secure compilation and transmission of existing medical records and diagnostic materials, institutional assignment based on the relevant subspecialty expertise, independent expert review by the receiving institution's clinical team, and transmission of a comprehensive written assessment with evidence-based recommendations. The timeline for a thorough second opinion evaluation typically ranges from one to four weeks depending on the complexity of the case and the need for additional diagnostic procedures. Throughout this process, the coordination function is strictly administrative — facilitating the organisational and logistical dimensions while respecting the absolute independence of the clinical evaluation and the patient's decision-making autonomy.
For complex fertility situations — including recurrent IVF failure, advanced maternal age, genetic considerations requiring preimplantation testing, male factor infertility requiring surgical sperm retrieval, and cases where regulatory frameworks in the patient's home country limit treatment options — Switzerland offers a distinctive combination of clinical expertise, genetic testing capabilities, strong regulatory oversight, and exceptional privacy protections. The regulatory framework established by the revised Federal Act on Medically Assisted Reproduction provides clear ethical boundaries while enabling access to contemporary reproductive technologies.
Beyond clinical capabilities, Switzerland offers several systemic attributes that are particularly relevant for complex international cases. System stability — Switzerland's political neutrality, economic stability, and mature institutional governance create an environment of predictability that is valued by patients navigating complex medical situations. Care predictability — the structured clinical pathway model, transparent cost framework, and established institutional protocols reduce uncertainty and facilitate planning. Coordination efficiency — compact geography, excellent transport infrastructure, and multilingual institutional capacity enable efficient movement between diagnostic, treatment, and rehabilitation phases. Rehabilitation infrastructure — Switzerland's globally recognised rehabilitation sector provides a natural continuum of care following acute treatment. Privacy framework — the combination of federal data protection legislation, medical professional secrecy, and institutional confidentiality culture provides a level of privacy protection that is among the strongest globally.
These attributes do not constitute a recommendation. The decision regarding where to seek medical evaluation or treatment is entirely personal and should be guided by the specific clinical situation, the relevant medical expertise available, and the patient's individual priorities and preferences. [Internal link: Why Switzerland Private Healthcare]
SwissAtlas operates as a neutral, non-medical institutional coordination platform. This positioning is fundamental to the integrity and value of the coordination service. SwissAtlas does not provide medical advice, clinical opinions, diagnostic assessments, or treatment recommendations under any circumstances. SwissAtlas does not evaluate, rank, endorse, or preferentially direct patients toward any specific medical institution, physician, or clinical programme.
The SwissAtlas coordination function encompasses exclusively non-clinical administrative and logistical services: the structuring and transmission of medical documentation, the identification of relevant institutional options based on the patient's stated requirements, the coordination of appointment scheduling and logistics, the management of accommodation, transport, and cultural support services, and the facilitation of communication between the patient's administrative contacts and institutional administrative personnel.
All clinical decisions — including the selection of a treating institution, the acceptance or rejection of proposed treatment plans, the pursuit or decline of second opinions, and all matters relating to medical care — are made exclusively by the patient in consultation with their chosen medical professionals. SwissAtlas's independence from any clinical role ensures that the coordination service operates without conflicts of interest and with complete alignment to the patient's autonomous decision-making.
This institutional positioning reflects SwissAtlas's commitment to operating within clearly defined boundaries that prioritise patient autonomy, institutional neutrality, and professional integrity. [Internal link: Private Coordination Services]
SwissAtlas is a non-medical coordination platform registered in Switzerland. SwissAtlas does not provide medical advice, clinical assessment, diagnostic services, treatment recommendations, or any form of healthcare service. All information presented on this page and throughout the SwissAtlas platform is provided for general educational and informational purposes only and does not constitute medical advice or a substitute for professional medical consultation.
SwissAtlas does not evaluate, rank, endorse, recommend, or express any preference regarding any medical institution, healthcare provider, clinical programme, or treatment modality. The coordination services provided by SwissAtlas are exclusively non-clinical and administrative in nature, encompassing logistical facilitation, documentation coordination, and communication support.
All medical decisions, including the selection of healthcare institutions, the acceptance or refusal of proposed diagnostic or treatment plans, and all matters relating to individual healthcare, are the sole responsibility of the patient and their chosen medical professionals. Patients are strongly encouraged to seek independent medical advice from qualified healthcare professionals before making any healthcare decisions.
The information provided on this page may not reflect the most current medical research, clinical guidelines, or institutional capabilities. Medical knowledge evolves continuously, and patients should rely on their treating physicians for current, individualised medical guidance.
The SwissAtlas coordination process for ivf / fertility follows a structured, four-phase framework designed to ensure administrative clarity, institutional alignment, and logistical precision at every stage. This process operates independently of all clinical decision-making, which remains exclusively within the domain of the patient and their chosen medical professionals.
The coordination process begins with a confidential written exchange, during which the patient or their representative provides a general description of the medical situation and coordination requirements. All communications are handled under strict confidentiality protocols consistent with Swiss data protection legislation. At this stage, SwissAtlas conducts a non-medical administrative assessment to understand the coordination needs, logistical requirements, and institutional preferences. No medical assessment, clinical opinion, or treatment recommendation is provided. The focus is exclusively on understanding the administrative and logistical dimensions of the coordination request.
Based on the general nature of the clinical situation and the patient's expressed requirements — including language preferences, privacy considerations, geographical preferences within Switzerland, treatment complexity, and logistical factors — appropriate Swiss institutions with relevant ivf / fertility capabilities are identified from SwissAtlas's curated network. This process is informational and facilitative only; no clinical recommendation or institutional ranking is provided. The patient retains complete autonomy in institutional selection. SwissAtlas provides structured information about institutional capabilities, international patient experience, and coordination readiness, enabling the patient to make an informed decision.
Once the patient has selected an institution and the clinical team has confirmed the proposed evaluation or treatment pathway, SwissAtlas facilitates the direct engagement between the patient and the institution. This includes the secure transmission of medical documentation in structured format, coordination of initial consultation scheduling, and establishment of direct communication channels between the patient's administrative contacts and the institution's international patient office. All clinical discussions, diagnostic assessments, and treatment planning occur directly between the patient and the treating medical team. SwissAtlas's role is limited to administrative facilitation and communication support.
Throughout the active treatment phase and beyond, SwissAtlas coordinates the logistical dimensions of the patient journey. This includes appointment scheduling, accommodation arrangements near the treating institution, private transport coordination, visa documentation support where required, interpreter arrangements, cultural accommodation planning — including dietary requirements and prayer facilities — and ongoing communication facilitation. For cases requiring post-treatment rehabilitation, coordination extends to rehabilitation facility identification, transfer logistics, and continuity planning. The final phase addresses the patient's transition back to their home healthcare environment, including comprehensive medical summary transmission, follow-up schedule coordination, and establishment of ongoing communication channels for institutional follow-up as directed by the treating medical team.
SwissAtlas remains non-medical throughout all phases. All clinical decisions are made exclusively by the patient in consultation with their chosen medical professionals.
A single IVF cycle in Switzerland typically spans four to six weeks from initial consultation to embryo transfer. The process begins with ovarian stimulation using injectable hormones for ten to fourteen days, during which regular ultrasound monitoring and blood tests guide dosage adjustments. Egg retrieval (oocyte collection) is performed under sedation and typically takes fifteen to thirty minutes. Fertilisation occurs in the laboratory, and embryo development is monitored for three to five days (to blastocyst stage in most Swiss centres). Embryo transfer is a brief outpatient procedure. A pregnancy test follows approximately two weeks later. However, the complete fertility evaluation — including hormonal assessment, hysteroscopy/hysterosalpingography, semen analysis, and potentially genetic testing — may require an additional one to four weeks before the treatment cycle begins. For international patients, SwissAtlas coordinates the timeline to minimise the number of required visits, with some monitoring potentially arranged in the patient's home country in collaboration with the Swiss centre.
IVF success rates depend on multiple factors including the woman's age, the underlying cause of infertility, embryo quality, the number of embryos transferred, and individual physiological factors. Swiss fertility centres report clinical pregnancy rates per embryo transfer that are consistent with leading European centres. Generally, cumulative pregnancy rates (across multiple cycles from a single egg retrieval, including frozen embryo transfers) provide a more meaningful picture than per-cycle rates. For women under 35, cumulative pregnancy rates per egg retrieval — including fresh and frozen embryo transfers — may exceed 60–70% at leading centres. Rates decline progressively with age, particularly after 40. Swiss centres participate in the European IVF Monitoring (EIM) programme and report outcomes to national registries, providing transparency and quality benchmarking. It is important to note that success rates are statistical averages and individual outcomes depend on multiple clinical factors that the treating fertility specialist will discuss in detail.
Switzerland offers a distinctive fertility treatment environment characterised by rigorous regulatory oversight, strong privacy protections, comprehensive genetic testing capabilities (preimplantation genetic testing has been permitted since 2017), and personalised care with smaller patient volumes per specialist. The legal framework — governed by the Federal Act on Medically Assisted Reproduction — provides clear ethical guidelines that protect patient interests. Compared to Spain and Czech Republic (popular European IVF destinations with lower costs), Switzerland offers stronger regulatory protections and privacy but at higher treatment costs. Compared to the US, Swiss IVF is significantly less expensive while achieving comparable clinical outcomes. Compared to the UK, Switzerland typically offers shorter waiting times for treatment. The choice of IVF destination should be guided by the specific clinical situation, regulatory considerations (particularly regarding genetic testing, egg donation, and embryo freezing policies), language and cultural preferences, and cost considerations.
IVF treatment costs in Switzerland are generally 40–60% lower than equivalent treatment at leading US fertility centres. A single IVF cycle in the US — including medications, monitoring, egg retrieval, laboratory procedures, and embryo transfer — may be significantly more expensive than in Switzerland. Medication costs, which constitute a substantial proportion of IVF expenses, are generally lower in Switzerland. Preimplantation genetic testing (PGT) is available in Switzerland at costs below US equivalents. Frozen embryo transfer cycles are also less expensive. However, cost comparisons should consider the full treatment journey including travel, accommodation, and potential need for multiple cycles. Swiss centres provide transparent, itemised cost estimates before treatment begins. SwissAtlas can provide general guidance on cost structure expectations.
IVF treatment is generally well-tolerated with minimal recovery time. After egg retrieval, most patients experience mild discomfort and can resume normal activities within one to two days. Ovarian hyperstimulation syndrome (OHSS) is a potential complication that in mild forms resolves within a few days but in severe forms may require medical attention and extended rest. After embryo transfer, no strict bed rest is required — normal daily activities are generally recommended, avoiding only strenuous exercise. The two-week waiting period between embryo transfer and pregnancy test can be spent at home or in Switzerland depending on patient preference and the treating centre's follow-up requirements. International patients should plan for a minimum stay of two to three weeks for a complete IVF cycle including egg retrieval and fresh embryo transfer. If a frozen embryo transfer is planned, the schedule can be more flexible with monitoring potentially arranged locally.
Preimplantation genetic testing (PGT) has been available in Switzerland since the 2017 revision of the Federal Act on Medically Assisted Reproduction. Swiss law permits PGT for two main indications: PGT-M (preimplantation genetic testing for monogenic/single-gene disorders) to prevent transmission of known hereditary conditions, and PGT-A (preimplantation genetic testing for aneuploidies) to screen embryos for chromosomal abnormalities. PGT-A is particularly relevant for women over 37, patients with recurrent implantation failure, recurrent pregnancy loss, or previous pregnancies with chromosomal abnormalities. The testing involves biopsy of a few cells from the embryo at the blastocyst stage (day 5–6), which are then analysed using next-generation sequencing (NGS) technology. Embryos are typically vitrified (frozen) while awaiting PGT results, with transfer of selected embryos in a subsequent cycle.
Under current Swiss law (Federal Act on Medically Assisted Reproduction), egg donation is not permitted in Switzerland. Sperm donation is legal and regulated. This regulatory framework reflects Swiss legislative and ethical considerations regarding assisted reproduction. For patients requiring egg donation, treatment must be sought in jurisdictions where it is legally permitted — such as Spain, Czech Republic, Greece, or the United States. SwissAtlas can provide coordination guidance for patients in this situation, helping them understand the regulatory landscape and logistical considerations. Swiss fertility specialists can provide comprehensive fertility evaluation and treatment planning, referring patients to partner centres abroad specifically for the egg donation component if needed.
Swiss law and clinical practice strongly favour single embryo transfer (SET) to minimise the risk of multiple pregnancies, which carry significantly higher health risks for both mother and babies. Elective single embryo transfer is the standard practice at leading Swiss fertility centres, particularly for women under 37 and those with good-quality blastocyst-stage embryos. In selected cases — typically for women over 37, those with previous failed cycles, or situations with lower embryo quality — transfer of two embryos may be considered following careful discussion of the risks and benefits. Swiss law permits the development of up to twelve embryos per treatment cycle (increased from three prior to 2017), which has improved success rates by enabling blastocyst culture, better embryo selection, and vitrification of surplus embryos for future use.
Swiss law permits the cryopreservation (vitrification) of embryos for future reproductive use. Embryos can be stored for up to ten years (with the possibility of extension under specific circumstances). The fate of cryopreserved embryos is determined by the couple's wishes, in accordance with Swiss legal requirements. Options include: use in a subsequent frozen embryo transfer cycle, continued storage, or allowing the embryos to thaw naturally (disposal). Swiss law does not currently permit embryo donation to other couples. The storage, management, and disposition of cryopreserved embryos are governed by detailed consent processes and the Swiss regulatory framework, which provides clear legal protections and ethical guidelines.
Fertility preservation options are well-established at Swiss centres and are particularly relevant for patients facing cancer treatment (oncofertility), those wishing to defer parenthood, and patients with medical conditions that may impact future fertility. Options include oocyte (egg) vitrification, embryo vitrification, ovarian tissue cryopreservation, and sperm cryopreservation. Egg vitrification for social or medical reasons is widely available, with survival rates exceeding 90% at experienced Swiss centres. For cancer patients, Swiss fertility centres collaborate closely with oncology teams to arrange emergency fertility preservation before chemotherapy or radiation begins — often within one to two weeks. Ovarian tissue cryopreservation is available for prepubertal patients or cases where egg retrieval is not feasible. SwissAtlas can coordinate urgent fertility preservation alongside oncology treatment coordination.
IVF in Switzerland is governed by the Federal Act on Medically Assisted Reproduction (Fortpflanzungsmedizingesetz, FMedG), revised in 2017. Key provisions include: IVF is available to married and unmarried heterosexual couples; up to twelve embryos may be developed per treatment cycle; preimplantation genetic testing (PGT-M and PGT-A) is permitted; embryo cryopreservation for up to ten years is permitted; single embryo transfer is the recommended standard; egg donation and surrogacy are prohibited; sperm donation is permitted; sex selection for non-medical reasons is prohibited. Swiss fertility centres are licensed and regularly inspected by cantonal health authorities. This comprehensive regulatory framework provides clear protections for patients and ensures that fertility treatment is conducted within defined ethical boundaries.
Fertility treatment is among the most private medical journeys a person or couple can undertake. Switzerland's Federal Act on Data Protection, combined with medical professional secrecy obligations and cantonal health legislation, provides among the strongest legal protections for patient privacy globally. All fertility treatment records — including diagnostic results, treatment protocols, genetic testing results, and pregnancy outcomes — are subject to strict data security requirements. Swiss fertility centres implement access controls, encryption, and audit trails for electronic medical records. For international patients who require absolute discretion, Switzerland's institutional and legal commitment to confidentiality provides significant assurance. SwissAtlas applies the same confidentiality standards to all coordination communications.
For international patients seeking comprehensive information about specific aspects of IVF treatment in Switzerland, SwissAtlas provides detailed guides covering key topics:
Each guide provides detailed, medically accurate information while maintaining SwissAtlas's non-medical coordination positioning. All content is designed to support informed decision-making for international patients considering fertility treatment in Switzerland.
SwissAtlas understands the sensitive and personal nature of fertility treatment. Our coordination services are designed with particular discretion:
Learn more about private coordination or how international patients access Swiss healthcare.
All medical decisions are made exclusively by the patient and their treating physicians.
Related pages: Healthcare Coordination · International Patients · GCC Families · Why Switzerland · Switzerland vs US · Clinics · Private Coordination
If you are managing a situation that requires immediate discretion and institutional-level coordination in Switzerland, we are available to respond within a few hours.
All enquiries are handled confidentially and without obligation.
Contact: contact@swissatlas.ch